化疗联合参麦注射液对晚期非小细胞肺癌患者细胞免疫及肿瘤恶性程度的影响(6)
[30]李莉.参麦注射液在肺癌综合治疗中的临床价值分析[J].临床医药文献电子杂志,2016,3(23):4680-4680,4681.
[31]汤建军.参麦注射液联合吉西他滨对老年非小细胞肺癌患者生活质量及免疫功能的影响[J].河南中医,2014,34(2):349-351.
[32]Wang X,Lin H,Liyuan LV,et al.A meta-analysis of Kang`ai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer[J].J Cancer Res Ther,2015,11(3):558-564.
[33]Remark R,Becker C,Gomez JE,et al.The non-small cell lung cancer immune contexture.A major determinant of tumor characteristics and patient outcome[J].Am J Respir Crit Care Med,2015,191(4):377-390.
[34]刘怀民,杨峰,王怀璋.参麦注射液对非小细胞肺癌化疗增效减毒作用的临床观察[J].四川中医,2007,25(8):72.
[35]Roepman P,Jassem J,Smit EF,et al.An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer[J].Clin Cancer Res,2009,15(1):284-290.
[36]王蓉,李大鵬,冯军.参麦注射液联合化疗对晚期非小细胞肺癌患者T细胞亚群及细胞因子的影响[J].南京中医药大学学报,2016,32(2):125-128.
[37]Molina R,Filella X,Augé JM,et al.Tumor markers (CEA,CA 125,CYFRA 21-1,SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis.Comparison with the main clinical and pathological prognostic factors[J].Tumour Biol,2003,24(4):209-218.
[38]李前进,潘杰.支气管动脉化疗栓塞联合放射性粒子植入治疗IIIa-IIIb期非小细胞肺癌后的肿瘤恶性程度评估[J].海南医学院学报,2016,22(15):1718-1721.
[39]Cedrés S,Nuez I,Longo M,et al.Serum tumor markers CEA,CYFRA21-1,and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)[J].Clin Lung Cancer,2011,12(3):172-179.
(2017-03-24收稿 责任编辑:王明), 百拇医药(罗丽华)
[31]汤建军.参麦注射液联合吉西他滨对老年非小细胞肺癌患者生活质量及免疫功能的影响[J].河南中医,2014,34(2):349-351.
[32]Wang X,Lin H,Liyuan LV,et al.A meta-analysis of Kang`ai injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer[J].J Cancer Res Ther,2015,11(3):558-564.
[33]Remark R,Becker C,Gomez JE,et al.The non-small cell lung cancer immune contexture.A major determinant of tumor characteristics and patient outcome[J].Am J Respir Crit Care Med,2015,191(4):377-390.
[34]刘怀民,杨峰,王怀璋.参麦注射液对非小细胞肺癌化疗增效减毒作用的临床观察[J].四川中医,2007,25(8):72.
[35]Roepman P,Jassem J,Smit EF,et al.An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer[J].Clin Cancer Res,2009,15(1):284-290.
[36]王蓉,李大鵬,冯军.参麦注射液联合化疗对晚期非小细胞肺癌患者T细胞亚群及细胞因子的影响[J].南京中医药大学学报,2016,32(2):125-128.
[37]Molina R,Filella X,Augé JM,et al.Tumor markers (CEA,CA 125,CYFRA 21-1,SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis.Comparison with the main clinical and pathological prognostic factors[J].Tumour Biol,2003,24(4):209-218.
[38]李前进,潘杰.支气管动脉化疗栓塞联合放射性粒子植入治疗IIIa-IIIb期非小细胞肺癌后的肿瘤恶性程度评估[J].海南医学院学报,2016,22(15):1718-1721.
[39]Cedrés S,Nuez I,Longo M,et al.Serum tumor markers CEA,CYFRA21-1,and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC)[J].Clin Lung Cancer,2011,12(3):172-179.
(2017-03-24收稿 责任编辑:王明), 百拇医药(罗丽华)